Switzerland· 62139001
Zelboraf 240 mg, Filmtabletten
A vemurafenib product containing vemurafenibum, registered in Switzerland by Roche Pharma (Schweiz) AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Vemurafenib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EC01 (vemurafenib), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Vemurafenib · ATC L01EC01
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of vemurafenib costs, country by country.
Normalised to the WHO defined daily dose (1.92 g), so markets compare like for like.
- Switzerland: $263.61 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Vemurafenib · price per daily dose (1.92 g)
USD · FX 28 Sept 2026
- CH Switzerland$263.61
The record
At a glance
Swissmedic (Switzerland)- Active substance
- vemurafenibum
- Manufacturer
- Roche Pharma (Schweiz) AG
- Country
- Switzerland (CH)
- ATC code
- L01EC01
- ATC class
- Vemurafenib
- Defined daily dose
- 1.92 g, O
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin768062139001356 StkCHF 1450.05
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
661 interactions on record for vemurafenib.
Graded by severity as the source publishes them — 264 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Vemurafenib · interactions on record
661 records
- 264 severe
- 377 moderate
- 20 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Vemurafenib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandZelborafParanova Oy
- United StatesZELBORAFGenentech, Inc.
- FranceZELBORAF 240 mg, comprimé pelliculéROCHE REGISTRATION (ALLEMAGNE)
- IrelandZelboraf 240 mg film-coated tabletsRoche Registration GmbH
- BelgiumZelboraf 240 mgRoche Registration
- NetherlandsZelboraf 240 mg, filmomhulde tablettenRoche Registration GmbH
- NorwayZelborafRoche Registration GmbH
- PolandZelborafRoche Registration GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zelboraf
- Liechtenstein · Zelboraf
- Norway · Zelboraf
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a16ce996-48e6-4814-a979-6ca01ed4e001 GET /v1/drugs/a16ce996-48e6-4814-a979-6ca01ed4e001?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "vemurafenibum 240 mg",
"valid_from": "2026-09-01",
"limitations": "[{\"description\":\"<!DOCTYPE html>\\n<html>\\n<head></head>\\n<body>\\n<p>In Kombination mit COTELLIC zur Behandlung von Patienten mit nicht resezierbarem oder metastasiertem Melanom mit BRAF-V600-Mutation. Nur bis zur Progression der Krankheit.<br>Die Behandlung bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br><br>Die Roche Pharma (Schweiz) AG vergütet nach Aufforderung durch denjenigen Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf die Kombination von ZELBORAF und COTELLIC dem Krankenversicherer für jede bezogene COTELLIC Packung (=Indikator für einen Behandlungszyklus) <strong>35.03%</strong> des Fabrikabgabepreises jeder COTELLIC Packung zurück. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden.<br><br>Der Indikationscode dieser Limitierung ist an den Krankenversicherer zu übermitteln.</p>\\n</body>\\n</html>\",\"costApproval\":null,\"indication\":\"19786.02\",\"isNew\":true,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-09-01\",\"validTo\":\"2029-08-31\"}]",
"galenic_form": "Filmtabl 240 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2012-04-01",
"self_retention_pct": 10
}See everything about vemurafenib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.